Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +0.27% 3-Year ROIIC % is -11.73 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 1,322 Biotechnology companies, Adlai Nortye ranks worse than 53.78% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Adlai Nortye's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -11.73%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Adlai Nortye's 3-Year ROIIC % or its related term are showing as below:
ANL's 3-Year ROIIC % is ranked worse than 53.78% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs ANL: -11.73
Adlai Nortye (NAS:ANL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Adlai Nortye 3-Year ROIIC % Related Terms
Adlai Nortye 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's 3-Year ROIIC % falls into.
Adlai Nortye's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -35.698 (Dec. 2025) - -67.27 (Dec. 2022) )
/
( 32.79 (Dec. 2025) - 301.967 (Dec. 2022) )
=
31.572
/
-269.177
=
-11.73%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Adlai Nortye (ANL) has a 3-Year ROIIC % of -11.73 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #711 out of 1322 companies in the Biotechnology industry, placing it in the top 53.8%.
Is Adlai Nortye's 3-Year ROIIC % too high?
Adlai Nortye's current 3-Year ROIIC % is -11.73. Based on the distribution chart, Adlai Nortye ranks #711 out of 1322 companies in the Biotechnology industry, which is below the industry midpoint.
How does Adlai Nortye's 3-Year ROIIC % compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #711 out of 1322 companies for 3-Year ROIIC %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current 3-Year ROIIC % is -11.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current 3-Year ROIIC % of -11.73. The current 3-Year ROIIC % is -11.73. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current 3-Year ROIIC % is -11.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
